Gilead Sciences (NASDAQ:GILD) Price Target Raised to $148.00

Gilead Sciences (NASDAQ:GILD) had its price target increased by Leerink Partners from $146.00 to $148.00 in a report issued on Wednesday,MarketScreener reports. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock.

Several other research firms have also recently issued reports on GILD. Needham & Company LLC increased their target price on Gilead Sciences from $140.00 to $170.00 and gave the stock a “buy” rating in a research report on Wednesday. Wall Street Zen cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. HSBC raised their target price on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research note on Wednesday, December 10th. Argus raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Finally, Daiwa Securities Group boosted their target price on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Twenty-three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $152.50.

Gilead Sciences Trading Up 2.1%

Shares of NASDAQ GILD opened at $154.98 on Wednesday. Gilead Sciences has a 52-week low of $93.37 and a 52-week high of $157.29. The company has a market cap of $192.28 billion, a PE ratio of 22.89, a P/E/G ratio of 1.22 and a beta of 0.36. The firm’s 50 day moving average price is $130.27 and its 200-day moving average price is $122.27. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.68.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. During the same quarter in the previous year, the firm posted $1.90 EPS. The firm’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts expect that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.1%. Gilead Sciences’s dividend payout ratio is presently 46.68%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the transaction, the director owned 8,920 shares of the company’s stock, valued at $1,115,713.60. This represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the transaction, the insider owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. This trade represents a 20.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 319,391 shares of company stock valued at $44,141,101 over the last three months. 0.27% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Large investors have recently bought and sold shares of the stock. GoalVest Advisory LLC increased its position in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares in the last quarter. Corundum Trust Company INC bought a new position in Gilead Sciences in the third quarter valued at approximately $26,000. Quattro Advisors LLC acquired a new position in Gilead Sciences during the fourth quarter worth $26,000. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences in the second quarter valued at $27,000. Finally, Ares Financial Consulting LLC acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $28,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported better-than-expected Q4 results and raised FY26 guidance, driving optimism about near-term revenue and EPS trends. Gilead Sciences, Inc. (NASDAQ:GILD) Just Reported And Analysts Have Been Lifting Their Price Targets
• Positive Sentiment: Major analysts lifted price targets and/or maintained Buy/Outperform ratings after the results — Wolfe Research to $170 (outperform), Oppenheimer to $165 (outperform), TD Cowen to $160 (buy), Deutsche Bank to $155 (buy) — signaling analyst conviction and providing upward pressure on the stock. Wolfe Research price target raise
• Positive Sentiment: BofA raised its price target to $162 and reiterated a Buy, reflecting post?earnings confidence in Gilead’s franchises. BofA raises PT
• Positive Sentiment: Additional buy ratings from large banks — J.P. Morgan and Scotiabank reiterated/issued Buy calls — adding to institutional endorsement after results. J.P. Morgan buy Scotiabank buy
• Positive Sentiment: Pipeline & product catalysts: Yescarta label expansion and continued HIV franchise momentum (Biktarvy, Descovy, Yeztugo) are being highlighted as durable growth drivers and part of the investment case. Yescarta label expansion & dividend growth
• Neutral Sentiment: Analyst commentary and research pieces (Zacks articles) are flagging Gilead as a momentum/value candidate and discussing whether the HIV portfolio can sustain growth — useful context but not immediate catalysts. Zacks momentum Zacks on HIV portfolio
• Neutral Sentiment: Short?interest reports in the feed show zero shares / NaN changes and a 0.0 days-to-cover — likely a reporting/data artifact rather than a meaningful market signal. (No external link available in the entry.)

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.